Study to investigate HDP-101

Trial Profile

Study to investigate HDP-101

Phase of Trial: Phase I

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs HDP 101 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
    • 12 Apr 2017 According to a Wilex AG media release, company plans to initiate this study in late 2018.
    • 30 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top